- Start
- Jul 30, 202690% CONFIDENCEfrom the source
Regeneron Q2 2026: Revenue Up 17% to US$4.3 Billion
- Second-quarter 2026 revenues rose 17% to US$4.3 billion versus the second quarter of 2025[1]
- Dupixent global net sales, recorded by Sanofi, rose 38% to an all-time high of US$6.0 billion; US EYLEA HD net sales rose 52% to US$596 million; Libtayo global net sales rose 30% to US$489 million[1]
- GAAP EPS was US$12.23, including a US$1.02 negative impact from acquired in-process R&D, and non-GAAP EPS was US$14.29[1]
- The Sanofi Development Balance was fully repaid by the end of the quarter[1]
- FDA and EMA accepted cemdisiran regulatory submissions for generalized myasthenia gravis, and CEO Leonard Schleifer cited about 50 clinical assets[1]
References 482% CONFIDENCEOverall confidence: 82%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
The first entry is always the pin's source. Overall confidence is a weighted average of how firmly each reference supports the start and end times used above; a reference counts half as much for every 180 days older than the newest.
- [1]90%biospace.com/press-releases/regeneron-reports-second-quarter-2026-financial-and-operating-resultsbiospace.com· Posted Oct 5, 2026· Starts Jul 30, 2026 ✓· 30% of score
The GlobeNewswire release is datelined 'TARRYTOWN, N.Y., July 30, 2026' and begins 'today announced financial results for the second quarter of 2026'; the finviz[2] and 1stOncology[3] copies are dated the same day.
- [2]80%Regeneron Reports Second Quarter 2026 Financial and Operating Results - Finvizfinviz.com· Published Jul 30, 2026· 23% of score
Copy of the release surfaced by search; not opened.[1]
- [3]70%Regeneron Reports Second Quarter 2026 Financial and Operating Results - 1stOncology1stoncology.com· Published Jul 30, 2026· 23% of score
Surfaced by search; not opened.[1]
- [4]85%Regeneron Form 8-K, Exhibit 99.1 (second quarter 2026 results)sec.gov· Published Jul 30, 2026· 23% of score
SEC exhibit surfaced by search; blocked to curl.
Suggest a correction
Something missing or wrong? Say it in your own words: a link that backs this pin up, a different start or end date and why, or a fact it lacks or gets wrong. The AI checks it against this pin's sources, searches for better ones, and adds any page that backs you up. The pin's own sources still count most. A picture that shows something else, or shows it badly, is looked at too, and moved down or replaced.
